DA5-CH

DA5-CH (KP405) (25 nmol/kg; intraperitoneal injection; once daily for 7 consecutive days) improves motor function, restores the levels of dopaminergic neuron markers, alleviates neuroinflammation, and increases the levels of neurotrophic factors in mice with MPTP (HY-W114750)-induced Parkinson's disease^[1].
DA5-CH (10 nmol/kg; i.p.; once daily; for 28 consecutive days) effectively improves working memory, spatial memory and cognitive flexibility in APP/PS1 transgenic Alzheimer's disease mice, reverses L-LTP impairment in the hippocampus, reduces Aβ plaque load and phosphorylated tau protein levels in the hippocampus, and normalizes the PI3K/AKT/GSK3β signaling pathway^[2].
DA5-CH effectively improves cognitive impairment and pathological symptoms in APP/PS1 mice by maintaining synaptic plasticity, reducing phosphorylated tau protein, and normalizing the activities of Pi3k and Akt^[6].
DA5-CH (10 nmol/kg; i.p.; once daily for 14 consecutive days) exerts neuroprotective effects in a rat model of Alzheimer's disease induced by intracerebroventricular injection of Streptozotocin (HY-13753), which reverses memory impairment, reduces tau protein phosphorylation levels, restores θ rhythmic activity, restores synaptic protein levels, alleviates mitochondrial stress, and reactivates growth factor signaling pathways^[3].
DA5-CH (50 nmol/kg; i.p.; single administration) crosses the blood-brain barrier at a higher rate than the tested single GLP-1 receptor agonists and other GLP-1/GIP dual receptor agonists^[3].
DA5-CH (0.1-10 mg/kg; i.p.; once daily; for 7 consecutive days) exerts potent neuroprotective effects in MPTP-induced mouse models of Parkinson's disease, and significantly improves motor function and increases the survival rate of dopaminergic neurons at doses of 1.0 mg/kg and 10 mg/kg^[5].
DA5-CH (50 nmol/kg; i.p.; single administration) exhibits better blood-brain barrier penetration efficacy than the tested single-receptor agonists and other dual agonists^[5].
DA5-CH (3×10⁶ cpm; intravenous injection; single dose) exhibits rapid blood-brain uptake and reaches equilibrium quickly, with its unidirectional influx constant likely ranging from 0.242 to 2.476 μl/g-min^[7].
DA5-CH (25 nmol/kg; i.p.; once every two days; for 31 consecutive days) exerts superior neuroprotective effects in 6-hydroxydopamine Parkinson's disease rat models, normalizing motor function, dopamine levels, inflammatory cytokine levels, α-synuclein levels and insulin signaling, while increasing the level of TH-positive neurons to be higher than that in sham-operated rats^[4].
DA5-CH (10 mg/kg; i.p.; once daily; for 7 consecutive days) exerts comprehensive neuroprotective effects on MPTP-induced Parkinson's disease mice, including restoring normal motor function, preserving dopaminergic neurons, alleviating neuroinflammation, oxidative stress and apoptosis, and restoring autophagic function^[5].